Graft-versus-host-disease and granulocyte colony-stimulating factor administration after allogeneic stem cell transplantation
Authors:
- 27 January 2005
- journal article
- Published by Springer Nature in Leukemia
- Vol. 19 (4) , 500-503
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Higher Mortality After Allogeneic Peripheral-Blood Transplantation Compared With Bone Marrow in Children and Adolescents: The Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant RegistryJournal of Clinical Oncology, 2004
- Treatment With Granulocyte Colony-Stimulating Factor After Allogeneic Bone Marrow Transplantation for Acute Leukemia Increases the Risk of Graft-Versus-Host Disease and Death: A Study From the Acute Leukemia Working Party of the European Group for Blood and Marrow TransplantationJournal of Clinical Oncology, 2004
- The effect of hematopoietic growth factors on the risk of graft-vs-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysisBone Marrow Transplantation, 2003
- Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin–based reduced-intensity preparative regimenBlood, 2003
- Hematopoietic stem cell transplantation for hematological malignancies in EuropeLeukemia, 2003
- Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized studyBlood, 2002
- Economic analysis of a phase III study of G-CSF vs placebo following allogeneic blood stem cell transplantationBone Marrow Transplantation, 2000
- Influence of recombinant human granulocyte colony-stimulating factor (filgrastim) on hematopoietic recovery and outcome following allogeneic bone marrow transplantation (BMT) from volunteer unrelated donorsBone Marrow Transplantation, 1999
- Granulocyte-colony-stimulating factor after allogeneic and autologous bone marrow transplantation in childrenMedical and Pediatric Oncology, 1996
- Human recombinant GM-CSF in allogeneic bone-marrow transplantation for leukaemia: double-blind, placebo-controlled trialThe Lancet, 1990